Dimensional Fund Advisors
PRLD icon

Dimensional Fund Advisors’s Prelude Therapeutics PRLD Stock Holding History

Dimensional Fund Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$120K Buy
+35,210
New +$92.3K ﹤0.01% 3103
2025
Q1 		– Sell
-10,981
Closed -$13.9K – 3349
2024
Q4 		$13.9K Sell
10,981
-18,101
-62% -$24K ﹤0.01% 3333
2024
Q3 		$60.3K Buy
29,082
+8
+0% +$37 ﹤0.01% 3282
2024
Q2 		$111K Buy
29,074
+14,769
+103% +$60.1K ﹤0.01% 3239
2024
Q1 		$67.8K Hold
14,305
– – ﹤0.01% 3310
2023
Q4 		$60.9K Buy
14,305
+3,117
+28% +$9.49K ﹤0.01% 3335
2023
Q3 		$34.5K Sell
11,188
-2,943
-21% -$11K ﹤0.01% 3408
2023
Q2 		$63.6K Buy
14,131
+1,372
+11% +$8.2K ﹤0.01% 3384
2023
Q1 		$72.7K Hold
12,759
– – ﹤0.01% 3352
2022
Q4 		$77 Sell
12,759
-1,857
-13% -$11.9K ﹤0.01% 3358
2022
Q3 		$97K Buy
+14,616
New +$98.5K ﹤0.01% 3338

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Dimensional Fund Advisors's PRLD Position: Q1 2026 in Review

Dimensional Fund Advisors opened a new position in Prelude Therapeutics (PRLD) in Q1 2026: 35,210 shares worth $120K. The stake represents ﹤0.01% of the portfolio and ranks #3103 among its holdings. This is a return to the name: Dimensional Fund Advisors previously reported a position in PRLD as recently as Q4 2024.

Dimensional Fund Advisors first reported a position in PRLD in Q3 2022 and has held it in 11 quarters since. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Dimensional Fund Advisors held 35,210 shares of Prelude Therapeutics worth $120K as of Q1 2026.
  • Prelude Therapeutics was a new Dimensional Fund Advisors position in Q1 2026.
  • Prelude Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #3103 holding.
  • Dimensional Fund Advisors first reported a position in Prelude Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.